Healios K.K. (HLOSF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Healios K.K. (HLOSF) trades at $1.80 with AI Score 47/100 (Grade C). Healios K. K. (HLOSF) is a biotechnology firm based in Tokyo, Japan, specializing in cell therapy and regenerative medicine. Market cap: $193.79M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for HLOSF: HLOSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HLOSF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HLOSF: the 1 perspectives are evenly split.
How is this calculated? →Healios K.K. (HLOSF) Healthcare & Pipeline Overview
Healios K.K. is a biotechnology company dedicated to advancing cell therapy and regenerative medicine, with a diverse pipeline targeting critical health issues, including age-related macular degeneration and ischemic stroke, positioning it as a significant player in the global healthcare landscape.
What Is the Investment Thesis for HLOSF?
Healios K.K. presents a compelling investment thesis driven by its robust pipeline of regenerative medicine products targeting significant health issues. The company's lead candidates, HLCR011 and HLCR012, are positioned to address age-related macular degeneration, a market projected to grow significantly due to the aging population. Furthermore, HLCL041 aims to tackle metabolic liver disease, which has seen increasing prevalence. The ongoing collaboration with Hyogo Medical University enhances Healios's research capabilities, particularly in eNK cell-based therapies for cancer, potentially unlocking new revenue streams. However, the company faces substantial risks inherent to the biotechnology sector, including the outcomes of clinical trials and regulatory approvals. Monitoring these factors will be crucial to understanding Healios's future growth trajectory.
Based on FMP financials and quantitative analysis
HLOSF Key Highlights
- Market Cap of $193.79M reflects the company's current valuation in the biotechnology sector.
- Profit Margin of -4235.1% indicates significant operational challenges and costs associated with research and development.
- Gross Margin of -529.7% highlights the company's early-stage investment in product development and commercialization.
- Beta of 1.40 suggests higher volatility compared to the broader market, typical for biotech firms.
- No dividend yield as the company reinvests earnings into R&D for future growth.
Who Are HLOSF's Competitors?
HLOSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HLOSF's Key Strengths?
- Innovative pipeline with multiple advanced therapies targeting significant health issues.
- Strong collaborative research agreements enhancing R&D capabilities.
- Established presence in key international markets.
What Are HLOSF's Weaknesses?
- High operational costs leading to negative profit and gross margins.
- Limited commercialized products, relying heavily on pipeline success.
- Small workforce may limit operational scalability.
What Could Drive HLOSF Stock Higher?
- Progress in clinical trials for HLCR011 and HLCR012, targeting age-related macular degeneration.
- Collaborative research with Hyogo Medical University on eNK cell-based cancer immunotherapies.
- Potential regulatory approvals for HLCL041 targeting metabolic liver disease.
What Are the Key Risks for HLOSF?
- Financial-distress signal — its Altman Z-Score of 1.00 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-75.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Outcomes of ongoing clinical trials may not meet expectations.
- Regulatory approvals may face delays or rejections.
- Market competition could impact the success of Healios's therapies.
What Are the Growth Opportunities for HLOSF?
- Growth opportunity 1: Healios's pipeline includes HLCR011 and HLCR012, targeting age-related macular degeneration, a condition affecting millions globally. The market for treatments in this area is projected to reach $11 billion by 2025, driven by the aging population. Healios's innovative approach using iPSC-derived therapies positions it to capture significant market share as it advances through clinical trials.
- Growth opportunity 2: The development of HLCL041 for metabolic liver disease taps into a growing market, with increasing cases of liver-related disorders. The global market for liver disease treatments is expected to exceed $20 billion by 2026. Healios's unique regenerative approach could provide a competitive advantage, especially as traditional therapies often fall short in efficacy.
- Growth opportunity 3: HLCM051, aimed at treating ischemic stroke and acute respiratory distress syndrome, addresses critical healthcare needs with limited current treatment options. The global market for stroke management is projected to grow to $34 billion by 2027, presenting Healios with an opportunity to introduce its innovative therapies.
- Growth opportunity 4: The collaboration with Hyogo Medical University on eNK cell-based cancer immunotherapies could lead to breakthroughs in cancer treatment. The global cancer immunotherapy market is expected to reach $300 billion by 2025, and Healios's focus on mesothelioma could position it favorably within this lucrative segment.
- Growth opportunity 5: Expansion into European and U.S. markets provides Healios with access to larger patient populations and advanced healthcare systems. As the company progresses through clinical trials and regulatory approvals, it could significantly enhance its market presence and revenue potential.
What Opportunities Does HLOSF Have?
- Expanding market for regenerative medicine and cell therapies.
- Potential for partnerships with larger pharmaceutical companies.
- Growing demand for innovative treatments in aging populations.
What Threats Does HLOSF Face?
- High competition in the biotechnology sector from established firms.
- Regulatory hurdles and lengthy approval processes for new therapies.
- Market volatility and investor sentiment affecting funding opportunities.
What Are HLOSF's Competitive Advantages?
- Strong focus on innovative regenerative medicine approaches.
- Unique pipeline of iPSC-derived therapies targeting critical health issues.
- Collaborative partnerships with leading medical institutions enhance research capabilities.
- Established presence in multiple key markets (Japan, Europe, U.S.) provides competitive advantage.
What Does HLOSF Do?
Founded in 2011 as Retina Institute Japan, K.K., Healios K.K. rebranded in 2013 and is headquartered in Tokyo, Japan. The company specializes in the innovation, development, production, and commercialization of cell therapy and regenerative medicine products. With a workforce of 65 employees, Healios operates across Japan, Europe, and the United States, focusing on advanced cellular and tissue-based therapies. Its pipeline includes iPSC-derived regenerative medicines such as HLCR011 and HLCR012, which address age-related macular degeneration, and HLCL041, targeting metabolic liver disease. Additionally, HLCM051 is a regenerative treatment aimed at ischemic stroke and acute respiratory distress syndrome, while HLCN061 is under development for solid tumor indications. Healios also collaborates with Hyogo Medical University to research eNK cell-based cancer immunotherapies for mesothelioma. This strategic focus on innovative therapies positions Healios as a forward-thinking entity in the biotechnology sector, addressing unmet medical needs through cutting-edge research and development.
What Products and Services Does HLOSF Offer?
- Develop and commercialize cell therapy and regenerative medicine products.
- Focus on advanced cellular and tissue-based therapies for various diseases.
- Operate in Japan, Europe, and the United States.
- Maintain a robust pipeline of innovative therapies targeting unmet medical needs.
- Collaborate with academic institutions for research and development.
- Utilize iPSC-derived technologies for regenerative treatments.
How Does HLOSF Make Money?
- Generate revenue through the commercialization of approved therapies.
- Engage in partnerships and collaborations for research and development.
- Leverage intellectual property from innovative therapeutic technologies.
- Seek funding through grants and public offerings to support R&D efforts.
What Industry Does HLOSF Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development. With a global market expected to reach $2.4 trillion by 2028, driven by advancements in personalized medicine and regenerative therapies, Healios K.K. is well-positioned to capitalize on these trends. The competitive landscape includes major players focusing on cell therapy and regenerative medicine, making Healios's specialized pipeline a critical differentiator in a crowded market.
Who Are HLOSF's Key Customers?
- Healthcare providers seeking advanced treatment options for patients.
- Research institutions and universities for collaborative projects.
- Patients suffering from age-related and metabolic diseases.
- Pharmaceutical companies interested in partnerships for therapy development.
Company Profile
Healios K.K. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Tadahisa S. Kagimoto. HLOSF has traded publicly since 2020.
F-Score 2/9Financial Health
Healios K.K.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.00 places it in the distress zone, a signal of elevated financial risk.
ROE -75%Key Financial Metrics
Return on equity for Healios K.K. stands at -75.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -14.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.7%, the inverse of the P/E and a quick read on earnings relative to price.
HLOSF Valuation & Market Position
With a $193.79M market cap, Healios K.K. sits in the micro-cap segment of the market. Relative to its peer group, HLOSF's quantitative score of 47/100 is below the peer average of 85/100.
FY2026 estForward Outlook
Wall Street analysts project Healios K.K. revenue of about $429.4M for fiscal 2026, with EPS near $-36.64. The estimate reflects 6 contributing analysts.
HLOSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative pipeline with multiple advanced therapies targeting significant health issues.
- Strong collaborative research agreements enhancing R&D capabilities.
- Established presence in key international markets.
- Upcoming: Progress in clinical trials for HLCR011 and HLCR012, targeting age-related macular degeneration.
Bear Case
- High operational costs leading to negative profit and gross margins.
- Limited commercialized products, relying heavily on pipeline success.
- Small workforce may limit operational scalability.
- Potential: Outcomes of ongoing clinical trials may not meet expectations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
HLOSF Latest News
-
Exploring High Growth Tech Stocks In Asia May 2026
Yahoo! Finance: HLOSF News · May 18, 2026
-
HEALIOS K.K. to Present at Jefferies Global Healthcare Conference
Yahoo! Finance: HLOSF News · May 14, 2026
HLOSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HLOSF.
Price Targets
Wall Street price target analysis for HLOSF.
HLOSF MoonshotScore
What does this score mean?
The MoonshotScore rates HLOSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Tadahisa S. Kagimoto
CEO
Tadahisa S. Kagimoto has been at the helm of Healios K.K. since its rebranding in 2013. With a background in biotechnology and extensive experience in the healthcare sector, he has played a pivotal role in steering the company's strategic direction. Kagimoto holds a degree in life sciences and has previously worked in various leadership roles within the industry, focusing on innovative therapeutic developments.
Track Record: Under Kagimoto's leadership, Healios has successfully developed a robust pipeline of regenerative therapies and established key partnerships with academic institutions, enhancing the company's research capabilities and market position.
HLOSF OTC Market Information
The OTC Other tier includes stocks that do not meet the listing requirements for higher tiers like NYSE or NASDAQ. Companies in this tier may have less stringent reporting requirements but can also face lower liquidity and higher volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower visibility and less stringent reporting standards compared to major exchanges.
- Potential for higher price volatility due to lower trading volumes.
- Limited access to institutional investors may impact stock liquidity.
- Review Healios's clinical trial results and pipeline status.
- Assess financial health through available reports and disclosures.
- Investigate partnerships and collaborations for research and development.
- Monitor regulatory developments affecting product approvals.
- Evaluate competitive landscape and market positioning.
- Established partnerships with reputable academic institutions.
- Presence in multiple key markets (Japan, Europe, U.S.).
- Strong focus on innovative research and development.
Common Questions About HLOSF (Healthcare)
What does Healios K.K. do?
Healios K.K. is a biotechnology firm focused on the development and commercialization of cell therapy and regenerative medicine products. The company has a diverse pipeline that includes therapies targeting age-related macular degeneration, metabolic liver disease, and ischemic stroke. With operations in Japan, Europe, and the United States, Healios aims to address significant health issues through innovative therapeutic approaches.
What are the main risks for HLOSF?
Healios K.K. faces several risks inherent to the biotechnology sector, including the potential for unfavorable outcomes in clinical trials, which could hinder the advancement of its product pipeline. Regulatory approval processes are often lengthy and uncertain, posing additional risks to the commercialization of its therapies. Furthermore, the competitive landscape in biotechnology is intense, with many established players vying for market share, which may impact Healios's ability to succeed.
What is Healios K.K.'s drug pipeline status?
Healios K.K. has a robust pipeline featuring several advanced therapies. Key candidates include HLCR011 and HLCR012, which are in development for age-related macular degeneration, and HLCL041, targeting metabolic liver disease. Additionally, HLCM051 is being developed for ischemic stroke and acute respiratory distress syndrome, while HLCN061 is focused on solid tumor indications. The company is actively progressing through various clinical trial phases, which are crucial for future commercialization.
What are the key factors to evaluate for HLOSF?
Healios K.K. (HLOSF) holds an AI score of 47/100 (low). Not financial advice.
How frequently does HLOSF data refresh on this page?
HLOSF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HLOSF's recent stock price performance?
Healios K.K. (HLOSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline with multiple advanced therapies targeting significant health issues. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HLOSF overvalued or undervalued right now?
Valuing Healios K.K. (HLOSF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HLOSF?
Before investing in Healios K.K. (HLOSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on available information as of June 2026. Financial metrics and company status may change over time.